[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"malignant-tumor\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:malignant-tumor":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,46,71,95,118,143,165,196,217,239,265,287,307,326],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100499307","alpha-radiation-emitters-device-dart-for-target-treatments-of-malignant-tumors-100499307",false,"NCT05781555","Alpha Radiation Emitters Device (DaRT) for Target Treatments of Malignant Tumors","A Prospective, Open Label, One Arm Study for a Compassionate Use of Diffusing Alpha Radiation Therapy","Inclusion Criteria:\n\n* Subjects with any malignancy\n* Subjects with a tumor size ≤ 7 centimeters in the longest diameter\n* Subjects over 18 years old\n* Subjects' life expectancy is more than 6 months\n* Women of childbearing potential (WOCBP) will have evidence of negative pregnancy test and are required to use an acceptable contraceptive method to prevent pregnancy for 3 months after treatment.\n* Subjects\u002FSurrogate decision maker are willing to sign an informed consent form\n\nExclusion Criteria:\n\n* Known hypersensitivity to any of the components of the treatment.\n* Clinically significant cardiovascular disease, e.g. cardiac failure of New York Heart Association classes III-IV, uncontrolled coronary artery disease, cardiomyopathy, uncontrolled arrhythmia, uncontrolled hypertension, or history of myocardial infarction in the last 12 months.\n* Any medical or psychiatric illness which in the opinion of the investigator would compromise the patient's ability to tolerate this treatment or interfere with the study endpoints.\n* Volunteers participating in another interventional study in the past 30 days which might conflict with the endpoints of this study or the evaluation of response or toxicity of DaRT.\n* Patients must agree to use adequate contraception (vasectomy or barrier method of birth control) prior to study entry, for the duration of study participation and for 3 months after discontinuing therapy.\n* High probability of protocol non-compliance (in opinion of investigator).\n* Subjects\u002FSurrogate decision maker not willing to sign an informed consent.\n* Women who are pregnant or breastfeeding.","ALL","18 Years",{"count":19,"type":20},100,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study is a Compassionate clinical study for the treatment of Malignant Tumors. The primary endpoint of the study is to assess the frequency, severity and causality of acute adverse events related to the DaRT treatment. Adverse events will be assessed and graded according to Common Terminology and Criteria for Adverse Events (CTCAE) version 5.0. The secondary endpoint is to assess the tumor response to DaRT treatment assessed using the Response Evaluation Criteria in Solid Tumors (RECIST) (Version 1.1) 3 months after DaRT seed insertion.",[26],"Malignant Tumor",[28,26,29,30,31,32],"Tumor","Cancer","Brachytherapy","Alpha emitting radiation","Compassionate treatment","RECRUITING","2026-06-15",{"date":36,"type":37},"2026-06-16","ACTUAL",{"date":39,"type":37},"2023-03-22",{"date":41,"type":20},"2027-04",{"name":43,"class":44},"Alpha Tau Medical LTD.","INDUSTRY",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":70},"100636556","phase-1-clinical-study-of-novel-therapeutic-vaccine-for-advanced-solid-tumors-100636556","NCT07567222","Clinical Study of Novel Therapeutic Vaccine for Advanced Solid Tumors","Safety, Tolerability, and Preliminary Antitumor Activity of Novel Therapeutic Tumor Vaccines in Advanced Solid Tumors","Inclusion Criteria\n\n1. Histologically or cytologically confirmed advanced solid tumors, or radiologically diagnosed HCC, eligible for one of the following study parts based on tumor type, clinical status, and prior treatment history:\n\n   Part A1: Patients with advanced osteosarcoma who achieved Stable Disease (SD) or Partial Response (PR) following first-line chemotherapy, and have at least one remaining lung metastatic lesion \\>= 0.5 cm.\n\n   Part A2: Patients with advanced osteosarcoma who have relapsed, metastasized, or progressed following prior chemotherapy, or who are intolerant to the toxicities of previous systemic therapy.\n\n   Part B1: Patients with advanced pancreatic cancer and disease progression following \\>= 1 prior line of standard systemic therapy.\n\n   Part C1: Patients with advanced HNSCC and disease progression following \\>= 2 prior lines of systemic therapy.\n\n   Part D1: Patients with advanced colon cancer and disease progression following \\>= 3 prior lines of therapy (including fluoropyrimidine, oxaliplatin, and irinotecan). Patients with RAS wild-type must have received EGFR inhibitors.\n\n   Part E1: Patients with advanced hepatocellular carcinoma (HCC) and disease progression following \\>= 2 prior lines of systemic therapy.\n\n   Part F1: Patients with advanced glioma and disease progression following the first-line Stupp regimen.\n\n   Part G1: Patients with advanced pancreatic cancer and disease progression following \\>= 1 prior line of therapy.\n\n   Part H1: Patients with advanced or recurrent metastatic breast cancer who have progressed on or after \\>= 3 prior lines of systemic therapy.\n2. Age 18-75 years.\n3. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2.\n4. Life expectancy \\> 3 months.\n5. Adequate organ function within 7 days prior to first dose, including:\n\n   Hematologic: Hemoglobin (Hb) \\>= 80 g\u002FL; White Blood Cell count (WBC) \\>= 3.0 x 10\\^9\u002FL; Platelet count (PLT) \\>= 80 x 10\\^9\u002FL; Absolute Neutrophil Count (ANC) \\>= 1.5 x 10\\^9\u002FL.\n\n   Hepatic: Total bilirubin \\\u003C= 1.5 x ULN (\\\u003C= 3 x ULN for liver metastases or HCC); ALT and AST \\\u003C= 2.5 x ULN (\\\u003C= 5 x ULN for liver metastases or HCC).\n\n   Renal: Creatinine clearance \\> 60 mL\u002Fmin (Cockcroft-Gault formula). Coagulation: International Normalized Ratio (INR) \\\u003C= 1.5 x ULN.\n6. At least one measurable or evaluable lesion per RECIST v1.1.\n7. Ability to understand and sign written informed consent and comply with study procedures.\n\nExclusion Criteria\n\n1. Another primary malignancy within 5 years prior to first dose, except for adequately treated non-melanoma skin cancer, carcinoma in situ, or localized low-risk cancers.\n2. Active central nervous system (CNS) metastases or leptomeningeal disease.\n3. Positive for infectious diseases, including HIV, active Hepatitis C (HCV RNA positive), or active Hepatitis B (HBsAg or HBcAb positive with HBV DNA \\>= 500 IU\u002FmL or \\>= 2000 copies\u002FmL).\n4. Active pulmonary tuberculosis.\n5. Active autoimmune disease requiring systemic treatment within the past 2 years; or use of systemic corticosteroids (\\> 10 mg\u002Fday prednisone equivalent) within 4 weeks prior to first dose.\n6. Major surgery or significant trauma within 28 days prior to enrollment, or presence of unhealed wounds, ulcers, or conditions associated with high risk of bleeding or perforation.\n7. Arterial\u002Fvenous thrombosis or pulmonary embolism within 6 months, or CTCAE Grade \\>= 3 bleeding event within 28 days prior to treatment.\n8. Localized conditions at the injection site (e.g., infection, inflammation, or extensive scarring) or clinically significant coagulation disorders that contraindicate subcutaneous or intraosseous administration.\n9. Known hypersensitivity or intolerance to study treatment components or related compounds.\n10. Pregnant or breastfeeding, or planning to conceive (participant or partner) during the study.\n11. Any condition that, in the investigator's judgment, may compromise safety or interfere with study participation or evaluation.","75 Years",{"count":55,"type":20},54,[57],"PHASE1","Advanced solid tumors remain a major therapeutic challenge due to their complex heterogeneity and the immunosuppressive tumor microenvironment (TME). Although cancer vaccines are designed to induce long-lasting antitumor immunity, their efficacy is often limited by the TME's immune-evasive mechanisms.\n\nBuilding on this rationale, investigators developed a novel vaccine comprising irradiated tumor cells and stromal cells isolated from adjacent non-cancerous tissues or tumor tissues in combination with adjuvant. Irradiated tumor cells in vaccines such as YMN102, YMN103, YMN104, YMN105, YMN106, and YMN107 are transfected with GM-CSF; the others, such as YMN101 and YMN108, are not transfected with GM-CSF. Preclinical studies across multiple tumor models have demonstrated potent antitumor activity with no significant toxicity observed following administration. This first-in-human Phase I study is designed to evaluate the safety and tolerability of this irradiated vaccine in patients with advanced solid tumors, alongside a preliminary assessment of its antitumor activity and immunogenic profile.\n\nThis is a first-in-human, Phase I, open-label study designed to evaluate the safety and tolerability of this novel vaccine. The study includes multiple arms targeting specific malignancies, including osteosarcoma, pancreatic cancer, HNSCC, colorectal cancer, HCC, glioma, and TNBC.\n\nThe primary objective is to determine the incidence of dose-limiting toxicities (DLTs). Secondary objectives include assessing the objective response, progression-free survival (PFS), and overall survival (OS) per RECIST v1.1. Exploratory analyses will monitor dynamic changes in circulating biomarkers and intratumoral immune modulation to identify potential predictive markers of clinical response.",[26],"2026-06-07",{"date":62,"type":37},"2026-06-09",{"date":64,"type":37},"2026-06-05",{"date":66,"type":20},"2027-06-30",{"name":68,"class":69},"West China Hospital","OTHER",2,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":82,"phases":4,"briefSummary":83,"conditions":84,"keywords":85,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":45},"100637423","first-in-human-study-of-the-radioligand-68ga--dota-epha2-100637423","NCT07593209","First-in-Human Study of the Radioligand 68Ga- DOTA-EphA2","Development and Evaluation of 68Ga-DOTA-EphA2: A Novel Imaging Agent Targeting EphA2 for Malignant Tumor","EphA2","Inclusion Criteria:\n\n* Adults aged 18-80 years\n* Patients with suspected or histologically confirmed malignant tumors At least one measurable lesion identified by conventional imaging (CT, MRI, or ultrasound)\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2\n* Ability to understand the study procedures and provide written informed consent\n* Adequate organ function allowing PET\u002FCT examination\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women\n* Severe hepatic, renal, cardiovascular, or pulmonary dysfunction considered --unsuitable for PET\u002FCT imaging\n* Known allergy or hypersensitivity to study-related compounds\n* Patients unable to tolerate PET\u002FCT examination or remain still during image acquisition\n* Participation in other investigational drug or radionuclide studies within 4 weeks prior to enrollment\n* Any medical or psychiatric condition judged by the investigators to interfere with study participation or interpretation of imaging results","80 Years",{"count":81,"type":20},30,"OBSERVATIONAL","Purpose Ephrin type-A receptor 2 (EphA2) is a receptor tyrosine kinase overexpressed in various solid tumors and associated with tumor progression, metastasis, and poor prognosis. However, noninvasive imaging tools for assessing EphA2 expression in vivo remain limited. This study aims to develop a novel 68Ga-labeled EphA2-targeting positron emission tomography (PET) tracer for specific imaging of EphA2-positive malignancies.",[26],[77],"2026-05-12",{"date":88,"type":37},"2026-05-18",{"date":90,"type":37},"2026-05-01",{"date":92,"type":20},"2027-12-31",{"name":94,"class":69},"First Hospital of China Medical University",{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":102,"targetDuration":4,"studyType":21,"phases":104,"briefSummary":105,"conditions":106,"keywords":107,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":45},"100567953","rehabilitation-outcomes-study-100567953","NCT06674889","Rehabilitation Outcomes Study","Cancer Survival and Outcomes Impact of Universal Disability Screening and Cancer Rehabilitation Referral Among Adults With Cancer Referred to the University of North Carolina","Inclusion Criteria:\n\n* Written informed consent obtained to participate in the study and HIPAA authorization for the release of personal health information.\n* Subjects are willing and able to comply with study procedures based on the judgement of the investigator.\n* Age ≥ 18 years at the time of consent.\n* The subject has been screened by the Central Oncology Navigation Program and referred to cancer care at the University of North Carolina Medical Center.\n* Answer \"yes\" to at least one of the following screening questions:\n\n  1. Does your health interfere with any of your activities of daily living (ADLs)?\n  2. Have you fallen, or do you feel unsteady while standing or walking?\n  3. Do you use durable medical equipment (DME)?\n  4. Are you interested in increasing the amount you exercise?\n\nExclusion Criteria:\n\n* Inability to read and understand the English language.\n* Psychological or other disability resulting in the inability to provide informed consent.\n* Unstable medical comorbidity that precludes safe participation in an exercise program, in the judgment of the clinical investigator.\n* Prisoners and other institutionalized individuals.",{"count":103,"type":20},60,[23],"This pilot health services interventional study aims to prospectively assess the effectiveness of a pre-treatment rehabilitation (prehabilitation) program across a diverse cohort of adult cancer patients via a randomized pilot trial. Upon screening and identification of high-risk features through a central navigation process, patients referred to oncology clinics will be approached to participate in tailored prehabilitation interventions. The study will track and analyze functional outcomes and quality of life aiming to demonstrate the comprehensive benefits of prehabilitation on the cancer treatment continuum. We hypothesize that this referral program is feasible and that those randomized to the intervention arm will have superior functional outcomes and global health-related quality of life.\n\nThe rationale for this study is anchored in the urgent need to optimize the cancer care trajectory for high-risk patients whose treatment outcomes and quality of life are jeopardized by the multifaceted challenges of their disease. While prehabilitation has shown potential to mitigate these adverse effects, the optimal methods for identifying and connecting these high-risk individuals to appropriate prehabilitation resources remain underexplored. This study, with its systematic approach to enrolling a diverse adult cancer population, endeavors to investigate not only the benefits of prehabilitation interventions but also the effectiveness of a targeted referral process. By doing so, it aims to uncover novel strategies for efficiently allocating prehabilitation resources, thereby enhancing the precision and impact of supportive cancer care.",[29,26],[108],"rehabilitation","2026-02-16",{"date":111,"type":37},"2026-02-17",{"date":113,"type":37},"2025-01-21",{"date":115,"type":20},"2027-01-20",{"name":117,"class":69},"UNC Lineberger Comprehensive Cancer Center",{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":124,"sex":16,"minAge":17,"maxAge":125,"enrollmentInfo":126,"targetDuration":4,"studyType":21,"phases":128,"briefSummary":130,"conditions":131,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":45},"100623714","phase-1-clinical-application-of-al18f-nota-fapi-04-petct-or-petmri-imaging-in-malignant-tumorcardiovascular-or-immune-disease-100623714","NCT07400224","Clinical Application of Al18F-NOTA-FAPI-04 PET\u002FCT or PET\u002FMRI Imaging in Malignant Tumor,Cardiovascular or Immune Disease","Inclusion Criteria:\n\n* a. Age 18 years old or above, gender not restricted. b. Have undergone a health check-up within the last 3 months (at least completed chest X-ray \u002F chest CT and abdominal B-ultrasound and other examinations), and no major diseases were found.\n\nExclusion Criteria:\n\n* As this study involves certain radiation exposure, patients who have had frequent radiation exposure due to clinical needs (those who have undergone a CT or PET\u002FCT examination once within 3 months or 1 month respectively) are not included in the study.",true,"88 Years",{"count":127,"type":20},600,[57,129],"PHASE2","This prospective, single-center study investigates the biodistribution, dosimetry, safety, diagnostic performance of Al18F-NOTA-FAPI PET imaging in patients with malignant tumor,cardiovascular or immune disease. And evaluates the potential of Al18F-NOTA-FAPI PET imaging in Clinical treatment strategy guidance.",[132,133,26],"Hyperthyroidism, Autoimmune","Cardiovascular Abnormalities","2026-02-03",{"date":136,"type":37},"2026-02-10",{"date":138,"type":37},"2022-05-10",{"date":140,"type":20},"2028-12-31",{"name":142,"class":69},"Peking Union Medical College Hospital",{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":4,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":150,"targetDuration":4,"studyType":21,"phases":152,"briefSummary":153,"conditions":154,"keywords":155,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":45},"100563600","effectiveness-of-central-oncology-navigation-and-the-use-of-an-orn-100563600","NCT06618274","Effectiveness of Central Oncology Navigation and the Use of an ORN","Navigation and Research: Evaluating the Intervention of Central Navigation and an Oncology Research Navigator (ORN) on Cancer Outcomes and Clinical Trial Enrollment (NAVIGATE Trial)","Inclusion Criteria:\n\nIn order to participate in this study a subject must meet all of the eligibility criteria outlined below.\n\n* Informed consent obtained to participate in the study and HIPAA authorization for release of personal health information.\n* Subject is willing and able to comply with study activities based on the judgement of the investigator.\n* Age ≥ 18 years at the time of consent.\n* Subject has a new patient appointment for cancer care at a UNC Medical Center and a confirmed cancer diagnosis.\n\nExclusion Criteria:\n\n* Lack of internet access.\n* Inability to understand the English language.\n* Psychological or other disability resulting in the inability to provide informed consent.",{"count":151,"type":20},686,[23],"This health services interventional study investigates the effectiveness of central oncology navigation (SOC ) alone and central oncology navigation with a new role called an \"oncology research navigator (ORN)\" who is embedded in central oncology navigation cancer care delivery. This study will examine two patient cohorts: Cohort 1 will enroll patients with new cancer appointments within genitourinary (GU) or thoracic cancers. These clinics have not yet implemented the central navigation program. Participants will be enrolled pre- and post-implementation of the central oncology navigator within these cancer groups to evaluate the effectiveness of the central oncology navigator alone. The second cohort will enroll participants with new cancer appointments within gastrointestinal (GI), hematology, and breast cancer (clinics where the central navigation program was implemented). These individuals will be randomized to receive standard of care, which for these cancer types includes central oncology navigation or the intervention of an oncology research navigator in addition to SOC. This intervention will involve baseline and biweekly follow-up for a total of 3 months. Interactions with the ORN will include facilitating participation in supportive care services and clinical trials. All participants will undergo baseline and follow-up patient-reported outcomes and data collection. The study will evaluate the impact of the central oncology navigation program alone, as well as the addition of the ORN on patient quality of life, as well as enrollment into studies and participation in supportive care services. Additional analyses will evaluate the impact of the central oncology navigation program on patient experience, patient activation, net promoter scores, and overall survival.",[29,26],[156],"navigation","2026-01-26",{"date":159,"type":37},"2026-01-28",{"date":161,"type":37},"2025-03-03",{"date":163,"type":20},"2031-07-01",{"name":117,"class":69},{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":172,"targetDuration":4,"studyType":21,"phases":174,"briefSummary":175,"conditions":176,"keywords":184,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":45},"100415211","phase-1-a-first-in-human-jab-8263-in-adult-patients-with-advanced-tumors-100415211","NCT04686682","A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors","A Phase I\u002FIIa, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-8263 in Adult Patients With Advanced Malignant Tumors","Inclusion Criteria:\n\n* Subjects must meet all the following criteria in order to be included in the research study:\n\n  1. Subject must be ≥18 years-of-age at the time of signature of the informed consent form (ICF).\n  2. Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.\n  3. Subjects with histologically or cytologically confirmed advanced solid tumors which have progressed despite standard therapy(ies), or are intolerant to standard therapy(ies), or have a tumor for which no standard therapy(ies) exists.\n  4. Subjects with recurrent\u002Frefractory AML according to WHO 2016\n  5. Subjects with life expectancy ≥3 months.\n  6. Patients with solid tumor must have at least one measurable lesion as defined by RECIST v1.1.\n  7. Patients who have sufficient baseline organ function.\n\nExclusion Criteria:\n\n1. History (≤3 years) of cancer that is histologically distinct from the cancer under study.\n2. Known serious allergy to investigational drug or excipients\n3. Active brain or spinal metastases\n4. History of pericarditis or Grade ≥2 pericardial effusion\n5. History of interstitial lung disease.\n6. History of Grade ≥2 active infections within 2 weeks\n7. Known human immunodeficiency virus (HIV) infection\n8. Seropositive for hepatitis B virus (HBV)\n9. Seropositive for hepatitis C virus (HCV), or HCV-RNA viral levels are not detectable.\n10. Any severe and\u002For uncontrolled medical conditions\n11. History of myocardial infarction, unstable angina pectoris, coronary artery bypass graft, or cerebrovascular accident\n12. Impaired cardiac function or clinically significant cardiac diseases\n13. QTcF \\>470 msec at screening\n14. History of medically significant thromboembolic events or bleeding diathesis\n15. Unresolved Grade \\>1 toxicity\n16. History of malignant biliary obstruction\n17. Pregnant or breast-feeding",{"count":173,"type":20},152,[57,129],"This is a Phase 1\u002F2a, first-in-human, open-label study of JAB-8263, this study has two parts: solid tumor dose escalation and expansion study and hematology tumor dose escalation and expansion study.\n\nThese two parts will determine the maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D) and assess the DLT of JAB-8263 in treatment with patients with advanced solid tumors and hematology tumors separately. 30 subjects each will be enrolled.",[177,178,179,180,181,182,183,26],"NSCLC","SCLC","CRPC","ESCC","Ovarian Carcinoma","AML","MF",[185,186],"BET inhibitor","Bromodomain and Extra-terminal","2026-01-08",{"date":189,"type":37},"2026-01-09",{"date":191,"type":37},"2021-05-07",{"date":193,"type":20},"2028-07",{"name":195,"class":44},"Jacobio Pharmaceuticals Co., Ltd.",{"id":197,"slug":198,"hasResults":11,"nctId":199,"briefTitle":200,"officialTitle":200,"acronym":4,"eligibilityCriteria":201,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":202,"targetDuration":204,"studyType":82,"phases":4,"briefSummary":205,"conditions":206,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":45},"100607805","psychological-distress-in-malignant-tumor-patients-effects-on-treatment-adherence-outcomes-and-quality-of-life-100607805","NCT07193329","Psychological Distress in Malignant Tumor Patients: Effects on Treatment Adherence, Outcomes, and Quality of Life","Inclusion Criteria:\n\n* (1) Confirmed malignant tumors by imaging or pathology (such as hepatobiliary carcinoma, gastric cancer, breast cancer, lung cancer, etc.)\n* (2) Planning to receive or currently undergoing systemic treatment (such as surgery, chemotherapy, TACE, targeted therapy, etc.)\n* (3) Age ≥18 years old\n* (4) Sign the informed consent form and voluntarily participate in this study\n\nExclusion Criteria:\n\n* (1) Combined with severe systemic diseases (such as severe cardiovascular and cerebrovascular diseases)\n* (2) There is severe cognitive impairment and it is impossible to complete the questionnaire assessment\n* (3) Incomplete clinical data or loss to follow-up",{"count":203,"type":20},2000,"3 Years","The goal of this observational study is to learn about the Psychological Distress in Malignant Tumor Patients about Effects on Treatment Adherence, Outcomes, and Quality of Life. The main question it aims to answer is:\n\nDoes Psychological Distress affect Malignant Tumor Patients' Effects on Treatment Adherence, Outcomes, and Quality of Life? Malignant Tumor Patients with or without Psychological Distress will answer GAD-7 and PHQ-9 and their Treatment Adherence, Outcomes, and Quality of Life be recorded for 3 years.",[207,26],"Psychological Distress","2025-09-18",{"date":210,"type":37},"2025-09-25",{"date":212,"type":37},"2025-07-22",{"date":214,"type":20},"2028-07-01",{"name":216,"class":69},"Gang Chen, MD",{"id":218,"slug":219,"hasResults":11,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":4,"eligibilityCriteria":223,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":224,"targetDuration":4,"studyType":82,"phases":4,"briefSummary":226,"conditions":227,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":45},"100505505","a-real-world-study-of-the-efficacy-and-safety-of-icis-as-first-line-therapy-for-advanced-malignancies-100505505","NCT05862259","A Real-world Study of the Efficacy and Safety of ICIs as First-line Therapy for Advanced Malignancies","A Multicenter, Multiomics, Non-interventional, Real-world Study of the Efficacy and Safety of Immune Checkpoint Inhibitors as First-line Therapy for Advanced Malignancies","Inclusion Criteria:\n\n1. Informed consent has been signed and, in the judgment of the investigator, the patient is able to comply with the study protocol and sign a written informed consent.\n2. the advanced malignant tumors (solid tumors of the non-small-cell lung carcinoma, stomach, breast, urinary system, etc.) were diagnosed by histopathology.\n3. the stage IV according to the eighth edition of IASLC.\n4. PS 0-2, the expected survival \\> 3 months.\n5. the age of 18-75 years.\n6. no contraindication to treatment with immune checkpoint inhibitors.\n\nExclusion Criteria:\n\n1. the patients' compliance was poor, which violated the rules of the trial;\n2. the patients with severe dysfunction of vital organs (heart, liver and kidney) ;\n3. the patients with other malignant tumors;\n4. the researchers considered that the patients should not participate in other conditions of the trial.",{"count":225,"type":20},120,"In this study, we collected the data of immunohistochemistry, gene detection, image, OS, PFS, Orr, and so on. Secondly, the database of immunotherapy for malignant tumor was established, and the predictive model was constructed to verify and establish the rationality and validity of the biomarkers and predictive system of immunotherapy",[26,228,229],"Immunotherapy","Artificial Intelligence","2025-07-11",{"date":232,"type":37},"2025-07-14",{"date":234,"type":37},"2023-08-10",{"date":236,"type":20},"2025-12-31",{"name":238,"class":69},"Xinqiao Hospital of Chongqing",{"id":240,"slug":241,"hasResults":11,"nctId":242,"briefTitle":243,"officialTitle":244,"acronym":245,"eligibilityCriteria":246,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":79,"enrollmentInfo":247,"targetDuration":4,"studyType":21,"phases":249,"briefSummary":250,"conditions":251,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":262,"locationsCount":264},"100477309","phase-1-first-in-human-trial-of-phox430-a-first-in-class-acetylglucosaminyltransferase-v-inhibitor-in-advanced-solid-tumours-100477309","NCT05495295","First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibitor, in Advanced Solid Tumours","An Adaptive First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibitor, in Patients With Advanced Solid Tumours (PhAST Trial)","PhAST","Inclusion Criteria:\n\n1. Histologically or cytologically confirmed diagnosis of cancer.\n\n   1. Dose escalation phase: patients with any solid tumour type or histology.\n   2. Expansion cohort 1: Patients affected by GBM.\n   3. Expansion cohort 2: Patients with triple-negative breast cancer (TNBC), defined as estrogen receptor (ER) negative (\\\u003C 1% of nuclei reacting for ER in IHC), progesterone receptor (PgR) negative (\\\u003C 1% of nuclei reacting for PgR in IHC), HER2 negative (IHC score = 0 or 1 or ICH score = 2 with FISH negative for HER2 overexpression. If only FISH was performed, negative result for HER2 overexpression).\n   4. Expansion cohort 3: Patients affected by solid tumour types selected by the PSC, on the basis of preclinical pharmacological data and of the antitumour activity observed during the dose escalation phase if any.\n2. Radiologically documented progressive disease after at least one prior treatment for metastatic\u002Fadvanced disease.\n3. Lack of standard effective treatment options.\n4. Female or male patients of ≥ 18 years and ≤ 80 years\n5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1. For GBM patients: Karnofsky Performance Status ≥ 50%.\n6. Recovery from acute reversible toxicities of previous treatment to Grade ≤ 1.\n7. Tumour tissue accessible for repeated biopsies (except GBM patients).\n8. For GBM patients: stable dose of corticosteroids for \\> 5 days before the baseline MRI scan.\n9. For non-GBM patients: Measurable disease as defined by Response Evaluation Criteria in Solid Tumours (RECIST) guideline V1.1 (specifically, no ascites, pleural or pericardial effusions, osteoblastic bone metastases, or carcinomatous lymphangitis of the lung as the only lesion). For GBM patients: Measurable disease as defined by RANO criteria.\n10. Adequate bone marrow function defined as:\n\n    1. absolute neutrophil count ≥ 1.5 x 109\u002FL (being \\> 2 weeks off hematopoietic growth factors),\n    2. platelet count ≥ 100 x 109\u002FL,\n    3. hemoglobin ≥ 9 g\u002Fdl without transfusions in the last 2 weeks.\n11. Adequate hepatic function defined as:\n\n    1. total bilirubin \\\u003C 1.5 x the upper limit of normal (ULN),\n    2. ALT \u002FAST (SGPT\u002FSGOT) \\\u003C 3 x ULN (\\\u003C 5 x ULN in the presence of known hepatic metastases),\n12. Adequate renal function defined as estimated glomerular filtration rate (eGFR) of \\> 50 ml\u002Fmin\u002F1.73 m2 according to the CKD-EPI formula.\n13. Adequate coagulation, defined as INR \\\u003C 1.5 and aPTT \\\u003C 1.5 × ULN. This applies only to patients who are not receiving therapeutic anticoagulation; patients receiving therapeutic anticoagulation should be on a stable dose.\n14. Written informed consent obtained prior to any trial-specific screening procedures.\n15. Life expectancy of at least 3 months\n16. Women of childbearing potential must have a negative serum pregnancy test obtained within 28 days prior to treatment start; in addition, the negative result is to be confirmed by a repeat urine or serum pregnancy test within 72 hours before study treatment start if the screening test was performed earlier.\n17. Female patients who are not postmenopausal (\"postmenopausal\" defined as ≥ 12 months of non-therapy-induced amenorrhea) or surgically sterile (absence of ovaries and\u002For uterus) must agree to practice a highly effective method of contraception throughout the study for at least 6 months after the last dose of study drug. Highly effective methods of contraception are those that alone or in combination result in a failure rate of a Pearl Index of \\\u003C 1% per year when used consistently and correctly. Sexual abstinence is only acceptable if it is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.\n18. Male patients must agree to remain sexually abstinent or use a condom during the treatment period and for at least 90 days after the last dose of study drug.\n19. Patients must be able to take IMP at home and to properly use the provided dosing device.\n\nExclusion Criteria:\n\n1. Major surgery, chemotherapy, radical radiotherapy, investigational agents, or other anticancer therapy in the last 4 weeks before treatment start.\n2. For all patients with the exception of GBM patients: active central nervous system (CNS) metastases, as indicated by clinical symptoms, cerebral edema, and\u002For progressive growth (subjects with a history of CNS metastases or cord compression are allowable if they have been definitively treated and have been clinically stable for at least 3 months, and off steroids or anticonvulsants, before day 1 treatment).\n3. For GBM patients: disease progression within three months following last prior radiation therapy.\n4. Inability or unwillingness to swallow.\n5. Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of the IMP (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, or malabsorption syndrome)\n6. Any other cancer within 3 years prior to enrolment, with the exception of adequately treated carcinoma in situ of the cervix uteri, or adequately treated basal or squamous cell carcinoma of the skin.\n7. Significant liver disease, including active viral, alcoholic or other hepatitis and cirrhosis.\n8. History of HIV infection, active hepatitis B (chronic or acute), or hepatitis C infection. Patients with past or resolved hepatitis B infection (defined as having a negative HBsAg test and positivity for antibodies for hepatitis B core antigen \\[anti-HBc\\]) are eligible. Patients positive for hepatitis C virus (HCV) antibody are eligible only if PCR is negative for HCV RNA\n9. Severe infections within 4 weeks prior to enrolment.\n10. Patients with a history of central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant and precluding informed consent or adversely affecting compliance with study drug.\n11. Baseline left ventricular ejection fraction (LVEF) \\\u003C 50% by echocardiography or multi-gated scintigraphic scan (MUGA)\n12. Other current severe, uncontrolled systemic disease\n13. Treatment with CYP3A4\u002F5 inhibitors within 5 drug elimination half-lives before study treatment start and\u002For inability or unwillingness to avoid such medications during study treatment\n14. Known hypersensitivity to any study drug components\n15. Pregnant or lactating women\n16. Patients deprived from liberty (for patients enrolled in France only)\n17. Patients who are not affiliated to a social security scheme or are not beneficiaries of such a scheme (for patients enrolled in France only)\n18. Adults under legal protection or unable to give their informed consent (for patients enrolled in France only)",{"count":248,"type":20},149,[57],"The PhAST Trial is an adaptive first-in-human clinical trial of the acetylglucosaminyltransferase V inhibitor PhOx430 in patients with advanced solid tumours conceived and designed with the contribution of the Gianni Bonadonna Foundation, a non-profit academic research institution aimed at promoting therapeutic innovation in oncology.. The trial includes two parts, a dose escalation phase which will enroll patients with non-selected tumour types, followed by a cohort expansion phase in selected tumour types.",[26,252,253,254],"Advanced Solid Tumor","Glioblastoma Multiforme","Metastatic Cancer","2025-04-07",{"date":257,"type":37},"2025-04-08",{"date":259,"type":37},"2022-07-18",{"date":261,"type":20},"2027-07-31",{"name":263,"class":44},"Phost'In Therapeutics",4,{"id":266,"slug":267,"hasResults":11,"nctId":268,"briefTitle":269,"officialTitle":270,"acronym":4,"eligibilityCriteria":271,"healthyVolunteers":124,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":272,"targetDuration":4,"studyType":21,"phases":274,"briefSummary":275,"conditions":276,"keywords":4,"overallStatus":277,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":279,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":285,"locationsCount":4},"100578368","impact-of-family-centered-empowerment-on-caregivers-of-children-with-cancer-a-quasi-experimental-study-protocol-100578368","NCT06810388","Impact of Family-Centered Empowerment on Caregivers of Children With Cancer: A Quasi-Experimental Study Protocol","Effect of a Family-centred Empowerment Model-based Intervention on the Caregiving Capacity and Preparedness of Caregivers of Children With Malignant Neoplasms: a Protocol for a Quasi-experimental Study","Inclusion Criteria: (1) children aged 0-18 years old, (2) those clinically diagnosed with malignant neoplasms, and (3) first-time visitors to our hospital.\n\nPrimary caregiver inclusion criteria: the caregiver is enrolled along with the child, (1) was ≥18 years of age; (2) was a member of the child's immediate family; (3) had cared for the child for the longest period among multiple caregivers; (4) had basic communication and reading skills and was proficient in Chinese; and (5) had no previous or current history of psychiatric illness or consciousness-related disorders.\n\nExclusion Criteria: (1)Children who abandon treatment or are transferred to a hospital while the study is in progress.",{"count":273,"type":20},128,[23],"The purpose of this trial is to understand the impact of a family empowerment-based intervention program on family caregivers' readiness to care and ability to care. It aims to elucidate whether a health education intervention program based on the Family Empowerment Model improves family caregivers' readiness for care and ability to care.\n\nParticipants will receive a health education program based on the family empowerment model and will complete questionnaires three days prior to admission, during hospitalization, and three days prior to discharge.This study is a non-pharmacological intervention and will not involve any changes in treatment or chemotherapy regimens.",[26],"NOT_YET_RECRUITING","2025-01-30",{"date":280,"type":37},"2025-02-05",{"date":282,"type":20},"2025-07-01",{"date":284,"type":20},"2026-07-01",{"name":286,"class":69},"Xiaowan Li",{"id":288,"slug":289,"hasResults":11,"nctId":290,"briefTitle":291,"officialTitle":292,"acronym":4,"eligibilityCriteria":293,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":294,"targetDuration":4,"studyType":82,"phases":4,"briefSummary":295,"conditions":296,"keywords":4,"overallStatus":277,"whyStopped":4,"lastUpdateSubmitDate":297,"lastUpdatePostDateStruct":298,"startDateStruct":300,"completionDateStruct":302,"leadSponsor":304,"locationsCount":45},"100486600","application-of-lars-ligament-in-bone-prosthesis-replacement-100486600","NCT05616182","Application of LARS Ligament in Bone Prosthesis Replacement","A Prospective, Real-world, Single-center, Cohort Study of LARS Ligaments in Bone Tumors","Inclusion Criteria:\n\nMen and women of all ages are welcome.\n\nPathologically confirmed in our hospital as a subtype of malignant tumor.\n\nHe received LARS ligament and bone prosthesis replacement at our hospital.\n\nExclusion Criteria:\n\nNot Applicable.",{"count":19,"type":20},"This is a single-center, prospective, real-world observational study designed to enroll all patients eligible for enrollment. Basic data, treatment methods, postoperative complications and limb function were collected. The differences in postoperative complications, postoperative limb function and so on between patients who underwent LARS ligament implantation and bone prosthesis replacement (ligament group) and patients who underwent bone prosthesis replacement (control group) were compared.",[26],"2024-01-22",{"date":299,"type":37},"2024-01-24",{"date":301,"type":20},"2024-12-30",{"date":303,"type":20},"2032-02-28",{"name":305,"class":306},"Henan Cancer Hospital","OTHER_GOV",{"id":308,"slug":309,"hasResults":11,"nctId":310,"briefTitle":311,"officialTitle":312,"acronym":4,"eligibilityCriteria":313,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":314,"targetDuration":4,"studyType":82,"phases":4,"briefSummary":316,"conditions":317,"keywords":4,"overallStatus":277,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":319,"startDateStruct":321,"completionDateStruct":323,"leadSponsor":325,"locationsCount":45},"100486601","application-of-3d-printed-prosthesis-in-limb-salvage-surgery-for-bone-tumors-100486601","NCT05616195","Application of 3D Printed Prosthesis in Limb Salvage Surgery for Bone Tumors","Application of 3D Printed Bone Prosthesis in Limb Salvage Surgery for Bone Tumors: a Single-center, Real-world Prospective Observational Study","Inclusion Criteria:\n\nMen and women of all ages are welcome.\n\nPathologically confirmed in our hospital as a subtype of malignant tumor.\n\nHe received 3D printed bone prosthesis replacement in our hospital.\n\nExclusion Criteria:\n\nNot applicable.",{"count":315,"type":20},80,"To report the patients who underwent 3D-printed bone prosthesis replacement in Henan Cancer Hospital in the next 10 years, and collect the postoperative complications and limb function of these patients.",[26],"2024-01-16",{"date":320,"type":37},"2024-01-18",{"date":322,"type":20},"2024-12-28",{"date":324,"type":20},"2032-12-30",{"name":305,"class":306},{"id":327,"slug":328,"hasResults":11,"nctId":329,"briefTitle":330,"officialTitle":331,"acronym":4,"eligibilityCriteria":332,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":333,"targetDuration":4,"studyType":82,"phases":4,"briefSummary":335,"conditions":336,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":340,"startDateStruct":342,"completionDateStruct":344,"leadSponsor":346,"locationsCount":45},"100485075","long-term-follow-up-of-anxiety-and-depression-in-patients-with-malignant-tumors-100485075","NCT05596344","Long-term Follow-up of Anxiety and Depression in Patients With Malignant Tumors","A Single-center, Real-world Prospective Observational Study of the Incidence and Development of Anxiety and Depression in Patients With Malignant Tumors","Inclusion Criteria:\n\n1. Men and women of all ages are welcome.\n2. Pathological diagnosis of malignant tumor in our hospital.\n3. Received at least one hospitalization at this hospital.\n4. The expected survival time is greater than 1 year.\n\nExclusion Criteria:\n\n1.There was no pathological report of malignancy.",{"count":334,"type":20},200,"This study was a single-center prospective, real-world observational study with plans to enroll all eligible patients. The basic information, anxiety and depression, treatment and prognosis of these patients were collected.",[26,337,338],"Anxiety","Depression","2023-11-10",{"date":341,"type":37},"2023-11-13",{"date":343,"type":37},"2023-05-20",{"date":345,"type":20},"2032-11-30",{"name":305,"class":306}]